Apomorphine still leads on speed as ropinirole finds its place

The debate over apomorphine versus ropinirole as a canine emetic is moving from theory to practice. Newer comparative evidence suggests both drugs can be effective, but they may not be interchangeable in every setting. While ropinirole brought something apomorphine never had in the U.S. market, an FDA-approved veterinary label, emergency-focused data now suggest IV apomorphine still has an edge when clinicians need the fastest and most reliable emesis possible. (pubmed.ncbi.nlm.nih.gov)

That distinction matters because ropinirole entered the market with a meaningful practical advantage. FDA approved Clevor (ropinirole ophthalmic solution) in June 2020 to induce vomiting in dogs, making it the first FDA-approved emetic for canine patients in the U.S. Earlier field data supporting ropinirole showed 95% of treated dogs vomited within 30 minutes, with a median time to first vomit of 10 minutes, and generally mild, transient ocular effects. The product’s ophthalmic route also offered a different workflow from injectable or conjunctival apomorphine, which has long been used in practice but is not FDA-approved for animal use in the U.S. (fda.gov)

The 2023 JAVMA study helped validate ropinirole in real-world cases. Investigators evaluated 279 client-owned dogs with suspected toxin or foreign material ingestion and found 91.4% vomited after ropinirole administration. A single dose worked in 78.9% of dogs, and overall evacuation of expected ingested material was 74.2%, statistically similar to previously reported apomorphine performance for gastric evacuation. Still, ropinirole was modestly less effective than apomorphine for inducing vomiting overall, and average time to emesis was 11 minutes. (pubmed.ncbi.nlm.nih.gov)

A 2025 prospective randomized clinical trial sharpened the comparison in emergency practice. Conducted from October 2021 through March 2023 at 2 specialty referral hospitals, the study enrolled 132 client-owned dogs after suspected or confirmed ingestion of a toxin or foreign body. Dogs were excluded if they were younger than 4.5 months, weighed less than 1.8 kg, had apparent ocular disease, had a history of central nervous system or hepatic disease, had ingested a substance for which emesis was contraindicated such as a caustic or volatile agent, or had already received antiemetics before presentation. Investigators tracked standard clinical data and a broad range of ingestion types, including toxic foods, plants, foreign material, cloth, medications, and rodenticides or other poisons. Dogs were randomized to ropinirole eye drops (63 dogs) or IV apomorphine (69 dogs); if vomiting did not occur within 20 minutes, the same dose was repeated, and dogs were monitored for 40 minutes. In that setting, ropinirole had a lower first-dose success rate than IV apomorphine, took longer to trigger the first emetic event, and was associated with more minor adverse events and more prolonged vomiting requiring rescue therapy. The authors concluded apomorphine was clinically superior for dogs presenting to the emergency department when rapid decontamination was needed. That aligns with a recent FDA compounding docket attachment arguing that compounded apomorphine may still be needed in situations where even short delays in emesis could worsen outcomes. (pubmed.ncbi.nlm.nih.gov)

Expert and industry commentary broadly reflects that same nuance. ASPCA toxicology guidance describes ropinirole ophthalmic as a newer option with a smaller evidence base than apomorphine, while Today’s Veterinary Practice and ASPCA toxicology materials continue to frame emesis induction as a case-by-case decision rather than a reflex step. VetGirl’s review of the 2025 trial similarly emphasized the real-world relevance of comparing the only FDA-approved veterinary emetic with extra-label standards already used in practice. Laura Stern, DVM, DABVT, DABT, writing in a 2025 peer-reviewed algorithmic review, emphasized that induction of emesis can reduce risk after toxic ingestion, but it is not benign and can lead to complications including protracted vomiting and aspiration pneumonia. (aspcapro.org)

Why it matters: For general practice, urgent care, and ER teams, the choice between these drugs is really a choice between convenience, regulatory status, and clinical performance. Ropinirole gives clinics an FDA-approved canine product delivered by eye drop, which may be attractive for stocking, training, and standardized protocols. But the newer head-to-head and emergency-setting data suggest apomorphine remains the stronger option when every minute counts, especially in high-risk toxicant exposures or foreign body ingestions where delayed emesis could reduce decontamination success. Veterinary teams may also need to think carefully about rescue antiemetic use, monitoring for prolonged vomiting, and which patients are poor candidates for emesis in the first place. That rescue piece may get easier to operationalize as newer antiemetic products reach the market: Dechra says its FDA-approved maropitant citrate injectable, Emeprev, a bioequivalent to the leading maropitant injectable, will be available through major veterinary distributors in early 2026, with no refrigeration requirement and benzyl alcohol included to reduce injection pain in dogs. (pubmed.ncbi.nlm.nih.gov)

The bigger takeaway is that this is not a winner-take-all story. Ropinirole appears to be an effective addition to the canine emesis toolkit, and its approval filled a real regulatory gap. But the accumulating evidence suggests its best role may be as an alternative rather than a full replacement for apomorphine, particularly outside the highest-acuity emergency scenarios. That may be the most useful framing for veterinary professionals building practical toxicology protocols. (pubmed.ncbi.nlm.nih.gov)

What to watch: Watch for updated toxicology algorithms, compounding policy discussions around apomorphine access, and whether future studies in real-world poisoning cases further define when ropinirole is “good enough” versus when apomorphine is clearly preferred. Also watch how clinics incorporate rescue antiemetic options into those pathways as newer injectable maropitant products become available and potentially simplify storage and patient comfort considerations. (todaysveterinarypractice.com)